An immediate priority for the advancement of psychedelic medicine is the execution of high quality research on the safety and efficacy of these experiences. At Neuma we believe in the potential that psychedelics have to revolutionize the way we approach mental health and overall wellness and aim to assist in the advancement of knowledge to support their effectiveness as a medicine, as a therapeutic and as a tool for enhancing individual and social wellness.
We are excited to announce that we are now offering the opportunity for individuals to learn more about and participate in upcoming psychedelic research trials that we are assisting with in Kingston. These trials will provide a safe and controlled environment for participants to explore the potential benefits of psychedelics under the guidance of our trained professionals. By participating in these trials, you will not only have the opportunity to improve your own mental health, but also contribute to the ongoing research and understanding of these powerful substances. If you are interested in learning more and potentially participating in one of our trials, please sign up to our mailing list.
Next Trial:
N500 Phase II Clinical Trial
We have partnered with ATMA to support the Ontario deliverability of the first of its kind N500 Phase II trial focused on psilocybin therapy for healthcare professionals.
*THIS TRIAL HAS BEEN POSTPONED. PLEASE JOIN THE WAITLIST BELOW TO RECEIVE FUTURE TRIAL UPDATES*
Join Our Community Newsletter
Neuma © 2022. All Rights Reserved | Icons created by Flaticon